Q BioMed Inc. Stock News

Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, C

Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada

Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline pois

Q BioMed Inc. (OTCQB:QBIO) said it has received a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differenti

Q BioMed Inc said it has seen an uptick in sales revenue from Strontium89, the company's potential chemotherapeutic drug, in its recently reported quarter. The company's second-quarter sales revenue

Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior safety and efficacy compared to the current FDA app

Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum of indications in large markets and its strategy w

Q BioMed Inc. (OTCQB:QBIO) has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its Uttroside-B (Utt-B) chemotherapeutic to treat liv

Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current pipeline of products and platforms.  “From incep

Q BioMed Inc. (OTCQB:QBIO) told shareholders that the company was seeing a significant uptrend in revenues, advancing its pipeline of assets, and was looking at an imminent up listing to the tech-domi

Autism Spectrum Disorder Therapeutics Market Key Companies Analyzed in this Report are Otsuka Holdings Co. Ltd. (Tokyo, Japan), Johnson & Johnson Services, Inc. (New Jersey, U.S.), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York, U.S.), Allergan (Dublin, Ireland), Q BioMed Inc (New York, U.S.), Hopebridge, LLC. (Indiana, U.S.), Eli Lilly and Company (Indiana, U.S.) Autism Spectrum Disorder Therapeutics Market Key Companies Analyzed in this Report are Otsuka Holdings Co. Ltd. (Tokyo, Japan), Johnson & Johnson Services, Inc. (New Jersey, U.S.), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York, U.S.), Allergan (Dublin, Ireland), Q BioMed Inc (New York, U.S.), Hopebridge, LLC. (Indiana, U.S.), Eli Lilly and Company (Indiana, U.S.)

Q BioMed Inc announced it has engaged EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89. 

Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 mo

Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 mo

Q BioMed Inc. has seen an uptick in Strontium89 (Strontium Chloride Sr-89 Injection, USP) sales in its fourth quarter.  As a result, the company said it is projecting its 4Q revenue will likely doubl